Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

The role of VEGF 165b in pathophysiology.

Peiris-Pagès M.

Cell Adh Migr. 2012 Nov-Dec;6(6):561-8. doi: 10.4161/cam.22439. Epub 2012 Oct 17. Review.

2.

The anti-angiogenic isoforms of VEGF in health and disease.

Qiu Y, Hoareau-Aveilla C, Oltean S, Harper SJ, Bates DO.

Biochem Soc Trans. 2009 Dec;37(Pt 6):1207-13. doi: 10.1042/BST0371207.

3.

Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis.

Manetti M, Guiducci S, Romano E, Ceccarelli C, Bellando-Randone S, Conforti ML, Ibba-Manneschi L, Matucci-Cerinic M.

Circ Res. 2011 Jul 22;109(3):e14-26. doi: 10.1161/CIRCRESAHA.111.242057. Epub 2011 Jun 2.

4.

[Alternative splicing of vascular endothelial growth factor A and ocular neovascularization].

Fan SJ, He SZ.

Zhonghua Yan Ke Za Zhi. 2011 Apr;47(4):373-7. Review. Chinese.

PMID:
21612688
5.

Splicing factor polymorphisms, the control of VEGF isoforms and association with angiogenic eye disease.

Carter JG, Cherry J, Williams K, Turner S, Bates DO, Churchill AJ.

Curr Eye Res. 2011 Apr;36(4):328-35. doi: 10.3109/02713683.2010.548892. Epub 2011 Feb 10.

PMID:
21309690
6.

Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis.

Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M, Damodoran G, Hagiwara M, Harper SJ, Woolard J, Ladomery MR, Bates DO.

J Biol Chem. 2010 Feb 19;285(8):5532-40. doi: 10.1074/jbc.M109.074930. Epub 2009 Nov 11.

7.

WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing.

Amin EM, Oltean S, Hua J, Gammons MV, Hamdollah-Zadeh M, Welsh GI, Cheung MK, Ni L, Kase S, Rennel ES, Symonds KE, Nowak DG, Royer-Pokora B, Saleem MA, Hagiwara M, Schumacher VA, Harper SJ, Hinton DR, Bates DO, Ladomery MR.

Cancer Cell. 2011 Dec 13;20(6):768-80. doi: 10.1016/j.ccr.2011.10.016.

9.

The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo.

Merdzhanova G, Gout S, Keramidas M, Edmond V, Coll JL, Brambilla C, Brambilla E, Gazzeri S, Eymin B.

Oncogene. 2010 Sep 30;29(39):5392-403. doi: 10.1038/onc.2010.281. Epub 2010 Jul 19.

PMID:
20639906
10.

Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis.

Shibuya M.

J Biochem Mol Biol. 2006 Sep 30;39(5):469-78. Review.

PMID:
17002866
11.

VEGF₁₂₁b and VEGF₁₆₅b are weakly angiogenic isoforms of VEGF-A.

Catena R, Larzabal L, Larrayoz M, Molina E, Hermida J, Agorreta J, Montes R, Pio R, Montuenga LM, Calvo A.

Mol Cancer. 2010 Dec 31;9:320. doi: 10.1186/1476-4598-9-320.

12.

SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases.

Oltean S, Gammons M, Hulse R, Hamdollah-Zadeh M, Mavrou A, Donaldson L, Salmon AH, Harper SJ, Ladomery MR, Bates DO.

Biochem Soc Trans. 2012 Aug;40(4):831-5. doi: 10.1042/BST20120051. Review.

PMID:
22817743
13.

Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors.

Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill AJ, Ladomery MR, Harper SJ, Bates DO.

J Cell Sci. 2008 Oct 15;121(Pt 20):3487-95. doi: 10.1242/jcs.016410.

14.

VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression.

Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO, Cui TG, Sugiono M, Waine E, Perrin R, Foster R, Digby-Bell J, Shields JD, Whittles CE, Mushens RE, Gillatt DA, Ziche M, Harper SJ, Bates DO.

Cancer Res. 2004 Nov 1;64(21):7822-35.

15.

Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor.

Perrin RM, Konopatskaya O, Qiu Y, Harper S, Bates DO, Churchill AJ.

Diabetologia. 2005 Nov;48(11):2422-7. Epub 2005 Sep 29.

PMID:
16193288
16.

Tissue stiffness regulates serine/arginine-rich protein-mediated splicing of the extra domain B-fibronectin isoform in tumors.

Bordeleau F, Califano JP, Negrón Abril YL, Mason BN, LaValley DJ, Shin SJ, Weiss RS, Reinhart-King CA.

Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8314-9. doi: 10.1073/pnas.1505421112. Epub 2015 Jun 23.

17.

Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling.

Awasthi N, Schwarz MA, Verma V, Cappiello C, Schwarz RE.

Lab Invest. 2009 Jan;89(1):38-46. doi: 10.1038/labinvest.2008.106. Epub 2008 Nov 10.

18.

Inhibition of high glucose-induced VEGF release in retinal ganglion cells by RNA interference targeting G protein-coupled receptor 91.

Hu J, Wu Q, Li T, Chen Y, Wang S.

Exp Eye Res. 2013 Apr;109:31-9. doi: 10.1016/j.exer.2013.01.011. Epub 2013 Feb 1.

PMID:
23379999
19.

Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.

Sun J, Blaskovich MA, Jain RK, Delarue F, Paris D, Brem S, Wotoczek-Obadia M, Lin Q, Coppola D, Choi K, Mullan M, Hamilton AD, Sebti SM.

Cancer Res. 2004 May 15;64(10):3586-92.

20.

Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.

Huang SW, Lien JC, Kuo SC, Huang TF.

Carcinogenesis. 2012 May;33(5):1022-30. doi: 10.1093/carcin/bgs127. Epub 2012 Mar 20.

PMID:
22436611

Supplemental Content

Support Center